Increasing FLT3-ITD length increases expression of bcl-xl in AML.

被引：0
|
作者：
Seedhouse, Claire H. [1 ]
Pallis, Monica [1 ]
Grundy, Martin [1 ]
Russell, Nigel [1 ]
机构：
[1] Univ Nottingham Hosp, City Hosp Campus, Clin Sci Building, Nottingham NG7 2UH, England
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.1909.1909
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1909
引用
收藏
页码：541A / 541A
页数：1
相关论文
共 50 条
  • [21] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    H Wu
    C Hu
    A Wang
    E L Weisberg
    W Wang
    C Chen
    Z Zhao
    K Yu
    J Liu
    J Wu
    A Nonami
    L Wang
    B Wang
    R M Stone
    S Liu
    J D Griffin
    J Liu
    Q Liu
    Leukemia, 2016, 30 : 754 - 757
  • [22] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jian-kang
    Wilson, Kelli
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2015, 126 (23)
  • [23] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
    Wu, H.
    Hu, C.
    Wang, A.
    Weisberg, E. L.
    Wang, W.
    Chen, C.
    Zhao, Z.
    Yu, K.
    Liu, J.
    Wu, J.
    Nonami, A.
    Wang, L.
    Wang, B.
    Stone, R. M.
    Liu, S.
    Griffin, J. D.
    Liu, J.
    Liu, Q.
    LEUKEMIA, 2016, 30 (03) : 754 - 757
  • [24] Influence of IDH on FLT3-ITD status in newly diagnosed AML
    Boddu, P.
    Takahashi, K.
    Pemmaraju, N.
    Daver, N.
    Benton, C. B.
    Pierce, S.
    Konopleva, M.
    Ravandi, F.
    Cortes, J.
    Kantarjian, H.
    DiNardo, C. D.
    LEUKEMIA, 2017, 31 (11) : 2526 - 2529
  • [25] Influence of FLT3-ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients
    Jiang, Xuejie
    Yin, Changxin
    Sun, Junya
    Cheng, Jiaying
    Wang, Qiang
    Yu, Guopan
    Jiang, Ling
    Xu, Dan
    Liu, Xiaoli
    Feng, Ru
    Liu, Qifa
    BLOOD, 2018, 132
  • [26] A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
    Long, Jun
    Chen, Xinjie
    Shen, Yan
    Lei, Yichen
    Mu, Lili
    Wang, Zhen
    Xiang, Rufang
    Gao, Wenhui
    Wang, Lining
    Wang, Ling
    Jiang, Jieling
    Zhang, Wenjun
    Lu, Huina
    Dong, Yan
    Ding, Yi
    Zhu, Honghu
    Hong, Dengli
    Sun, Yi Eve
    Hu, Jiong
    Liang, Aibin
    CELL REPORTS MEDICINE, 2023, 4 (11)
  • [27] Influence of IDH on FLT3-ITD status in newly diagnosed AML
    P Boddu
    K Takahashi
    N Pemmaraju
    N Daver
    C B Benton
    S Pierce
    M Konopleva
    F Ravandi
    J Cortes
    H Kantarjian
    C D DiNardo
    Leukemia, 2017, 31 : 2526 - 2529
  • [28] ASXL1-Mutated Donor HSCs Evolved into FLT3-ITD Positive AML in the Unrelated Donor and FLT3-ITD Negative AML in the Recipient after Transplant
    Liu, Zhongwen
    Liu, Hongxing
    Zhang, Yanli
    Kong, Dai
    Shi, Jie
    Zhang, Yin
    Wen, Meiying
    Song, Yongping
    Tong, Chunrong
    Chen, Mingyi
    Murphy, William J.
    Sun, Kai
    BLOOD, 2015, 126 (23)
  • [29] Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML
    Wang, Aoli
    Wu, Hong
    Chen, Cheng
    Hu, Chen
    Qi, Ziping
    Wang, Wenchao
    Yu, Kailin
    Liu, Xiaochuan
    Zou, Fengming
    Zhao, Zheng
    Wu, Jiaxin
    Liu, Juan
    Liu, Feiyang
    Wang, Li
    Stone, Richard M.
    Galinksy, Ilene A.
    Griffin, James D.
    Zhang, Shanchun
    Weisberg, Ellen L.
    Liu, Jing
    Liu, Qingsong
    ONCOTARGET, 2016, 7 (20) : 29131 - 29142
  • [30] FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS
    Sampath, D.
    Mali, R.
    Lasater, E.
    Doyle, K.
    Malla, R.
    Boghaert, E.
    Souers, A.
    Leverson, J.
    HAEMATOLOGICA, 2017, 102 : 42 - 42
12345